couter

4593.THealios K.K.

Health CareBiotechnology
Nov 12, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Thu12Nov

    Q3 FY26 earnings print assessing revenue trajectory and cash runway amid ongoing pipeline clinical trials.

  • Fri12Feb

    Full-year results and initial forward guidance for FY27, focusing on R&D expenditure and cash preservation.

  • Tue20Apr

    Topline safety and initial efficacy data for the company's induced pluripotent stem cell-derived NK cell program.

  • Fri14May

    First-quarter earnings print testing whether clinical momentum translates into operational or partnership revenue.

  • Thu15Jul

    Outcome of formal consultation with the Japanese PMDA regarding accelerated regenerative medicine approval pathways.